Streetbeat News

HTGM

HTG Molecular Diagnostics Inc

htgmolecular.com

CEO

John Lubniewski

Employees

Industry

Analytical Laboratory Instrument Manufacturing

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.

Open

0.57

Mkt cap

1.1M

Volume

725K

High

0.48

P/E Ratio

-0.03

52-wk high

24.96

Low

0.48

Div yield

N/A

52-wk low

0.46

Asset Entities Inc. shares surged 142% after announcing the development of an AI bot for its AE360DDM suite of services on Discord. Other stocks experienced significant movement in Monday's mid-day session, with several companies reporting new developments, acquisitions, and analyst upgrades.

Portfolio Pulse from Lisa Levin

June 12, 2023 | 5:04 pm

On Wednesday, 29 companies set new 52-week lows, with NovoCure being the largest in terms of market cap and HTG Molecular Diagnostics being the smallest. PolarityTE's stock fell the most, while Owlet's shares rebounded the highest.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 4:38 pm

On Tuesday, 69 stocks hit new 52-week lows, with Estee Lauder being the largest company by market cap to set a new low. Westport Fuel Systems shares dropped the most, while Greenidge Generation Hldg shares rebounded the highest.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 5:54 pm

HTG Molecular Diagnostics (NASDAQ:HTGM) filed for Chapter 11 bankruptcy, causing its stock to plunge. The company will operate as a debtor-in-possession business during the bankruptcy and is seeking first-day motions to continue normal operations. HTG Molecular reported Q1 sales of $1 million, with a net loss of $5 million.

Portfolio Pulse from Vandana Singh

June 06, 2023 | 5:47 pm

During Tuesday's intraday session, several healthcare stocks experienced significant price movements. Hoth Therapeutics, Synlogic, Castle Biosciences, Tenon Medical, eFFECTOR Therapeutics, and AlloVir were among the gainers, while HTG Molecular Diagnostics, NovoCure, VistaGen Therapeutics, NRX Pharmaceuticals, TransCode Therapeutics, and Myomo were among the losers.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 5:31 pm

THOR Industries shares rose 14.6% after reporting better-than-expected Q3 results and raising FY23 EPS guidance. Other stocks with significant movements include Recruiter.com Group, Hoth Therapeutics, Visionary Education Technology Holdings Group, and Zura Bio Limited.

Portfolio Pulse from Lisa Levin

June 06, 2023 | 5:05 pm

Bluejay Diagnostics shares are trading lower by 12% in pre-market trading. The article also lists 20 stocks moving premarket, with Visionary Education Technology Holdings Group, Chijet Motor Company, and Secoo Holding Limited among the top gainers, while HTG Molecular Diagnostics, Pasithea Therapeutics Corp, and Sono Group N.V. are among the top losers.

Portfolio Pulse from Lisa Levin

June 06, 2023 | 12:36 pm

During Monday's intraday session, several healthcare stocks experienced significant price movements. Gainers included INVO Bioscience, Timber Pharmaceuticals, Pasithea Therapeutics, Regencell Bioscience, Replimune Group, and Scilex Holding. Losers were Bellerophon Therapeutics, Castle Biosciences, Mallinckrodt, PDS Biotechnology, HTG Molecular Diagnostics, and Elevation Oncology.

Portfolio Pulse from Benzinga Insights

June 05, 2023 | 5:31 pm

During Tuesday's morning session, 137 companies made new 52-week lows. Notable companies include Bristol-Myers Squibb, NovaBay Pharmaceuticals, Smart for Life, and Nemaura Medical.

Portfolio Pulse from Benzinga Insights

May 30, 2023 | 6:13 pm

HTG Molecular Diagnostics received a notice of delisting or failure to satisfy a continued listing rule or standard from Nasdaq on May 18.

Portfolio Pulse from Charles Gross

May 24, 2023 | 9:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.